Key result
Dexmedetomidine and clonidine significantly reduced the incidence of ventricular tachyarrhythmias to 42% and 56%, respectively, compared to 93% with saline in a rabbit model of acquired long QT syndrome.
Why the study?
Do alpha-2 adrenoreceptor agonists (dexmedetomidine and clonidine) inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome?
Population
73 Japanese white rabbits in a methoxamine-sensitized model of acquired long QT syndrome
Comparison
Dexmedetomidine (1 μg·kg·min) or clonidine (33.3… vs Saline solution administered intravenously
Design
Preclinical
Follow-up
Up to 20 minutes
Authors
Loading...
Supports alpha-2 agonist testing in LQTS models; leaves open clinical translation to human arrhythmia prevention.
Do alpha-2 adrenoreceptor agonists (dexmedetomidine and clonidine) inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome?
Absolute Event Rate: 42% vs 93%
p-value: p=<0.01
Alpha-2 adrenoreceptor agonists, particularly dexmedetomidine, suppress ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome, suggesting a potential therapeutic role for abnormal repolarization-related VTs.
Tsutsui et al. (2012) studied Acquired long QT syndrome (n=73). Dexmedetomidine and Clonidine vs. Saline was evaluated on Incidence of ventricular tachyarrhythmias (VTs) (p=<0.01). Dexmedetomidine and clonidine significantly reduced the incidence of ventricular tachyarrhythmias to 42% and 56%, respectively, compared to 93% with saline in a rabbit model of acquired long QT syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: